JP5913130B2 - 治療用アピラ−ゼ構築物、アピラ−ゼ作用物質、及び製造方法 - Google Patents

治療用アピラ−ゼ構築物、アピラ−ゼ作用物質、及び製造方法 Download PDF

Info

Publication number
JP5913130B2
JP5913130B2 JP2012549089A JP2012549089A JP5913130B2 JP 5913130 B2 JP5913130 B2 JP 5913130B2 JP 2012549089 A JP2012549089 A JP 2012549089A JP 2012549089 A JP2012549089 A JP 2012549089A JP 5913130 B2 JP5913130 B2 JP 5913130B2
Authority
JP
Japan
Prior art keywords
apyrase
seq
sequence
apilase
cd39l3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012549089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516991A5 (https=
JP2013516991A (ja
Inventor
チェン，リードン
ジョン，スン，ソン
Original Assignee
エイピーティー セラピューティックス，インク．
エイピーティー セラピューティックス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイピーティー セラピューティックス，インク．, エイピーティー セラピューティックス，インク． filed Critical エイピーティー セラピューティックス，インク．
Publication of JP2013516991A publication Critical patent/JP2013516991A/ja
Publication of JP2013516991A5 publication Critical patent/JP2013516991A5/ja
Application granted granted Critical
Publication of JP5913130B2 publication Critical patent/JP5913130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2012549089A 2010-01-13 2011-01-13 治療用アピラ−ゼ構築物、アピラ−ゼ作用物質、及び製造方法 Active JP5913130B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29469510P 2010-01-13 2010-01-13
US61/294,695 2010-01-13
PCT/US2011/021187 WO2011088244A1 (en) 2010-01-13 2011-01-13 Therapeutic apyrase constructs, apyrase agents, and production methods

Publications (3)

Publication Number Publication Date
JP2013516991A JP2013516991A (ja) 2013-05-16
JP2013516991A5 JP2013516991A5 (https=) 2014-02-27
JP5913130B2 true JP5913130B2 (ja) 2016-04-27

Family

ID=44304650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549089A Active JP5913130B2 (ja) 2010-01-13 2011-01-13 治療用アピラ−ゼ構築物、アピラ−ゼ作用物質、及び製造方法

Country Status (10)

Country Link
US (1) US8771683B2 (https=)
EP (1) EP2523971B1 (https=)
JP (1) JP5913130B2 (https=)
KR (1) KR20130009744A (https=)
AU (1) AU2011205248A1 (https=)
BR (1) BR112012017243A2 (https=)
CA (1) CA2787016C (https=)
IL (1) IL220882A0 (https=)
RU (1) RU2012134366A (https=)
WO (1) WO2011088244A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2941254B1 (en) * 2014-03-12 2017-01-11 Shiseido Company, Ltd. Agent for sedating response to external stimulation in skin and method for sedating that response technical field
CN105018442A (zh) * 2014-04-23 2015-11-04 Apt治疗公司 改进的en-腺苷三磷酸双磷酸酶
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CA3098818A1 (en) 2020-08-19 2022-02-19 Astrazeneca Ab Combination treatment
JP7547996B2 (ja) * 2020-12-22 2024-09-10 トヨタ自動車株式会社 コイルの製造方法
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
KR100545945B1 (ko) * 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
EP1733045A4 (en) 2004-02-27 2008-08-13 Apt Therapeutics Inc DESIGN AND THERAPEUTIC USE OF ADPASE-ENHANCED APYRASES
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法

Also Published As

Publication number Publication date
EP2523971A4 (en) 2013-06-05
EP2523971B1 (en) 2015-02-25
RU2012134366A (ru) 2014-02-20
AU2011205248A1 (en) 2012-08-02
CA2787016C (en) 2018-01-23
US8771683B2 (en) 2014-07-08
CA2787016A1 (en) 2011-07-21
EP2523971A1 (en) 2012-11-21
JP2013516991A (ja) 2013-05-16
BR112012017243A2 (pt) 2017-09-19
KR20130009744A (ko) 2013-01-23
US20130142775A1 (en) 2013-06-06
WO2011088244A1 (en) 2011-07-21
IL220882A0 (en) 2012-09-24

Similar Documents

Publication Publication Date Title
JP7418519B2 (ja) 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
JP5913130B2 (ja) 治療用アピラ−ゼ構築物、アピラ−ゼ作用物質、及び製造方法
CA2737094C (en) Factor ix polypeptide mutant, its uses and a method for its production
CN102153653B (zh) 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
US20250179447A1 (en) Solubilized apyrases, methods and use
US20250092116A1 (en) Methods of producing long-acting coagulation factors
KR101672108B1 (ko) 패혈증의 치료 및/또는 개선을 위한 의약
JP2009533364A (ja) 治療用ポリペプチドのインビボでの回収を増大させる方法
KR101486835B1 (ko) 고순도 가용성 트롬보모듈린 및 그 제조 방법
CN105018442A (zh) 改进的en-腺苷三磷酸双磷酸酶
AU2016375187B2 (en) Soluble glycoprotein V for treating thrombotic diseases
CN115243710A (zh) 用于治疗动脉和静脉血栓形成的协同且靶向的组合物
WO2004092218A1 (ja) 組換えアンチトロンビンの製造方法
HK1179654B (en) High-purity soluble thrombomodulin and method for producing same
HK1260028B (en) Soluble glycoprotein v for treating thrombotic diseases
HK1260028A1 (en) Soluble glycoprotein v for treating thrombotic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160401

R150 Certificate of patent or registration of utility model

Ref document number: 5913130

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250